Skip to main content

Site notifications

Notice for concizumab (Novo Nordisk Pharmaceuticals Pty Ltd)

Active ingredients
concizumab
Date of review outcome
Lapse date
Type
Priority review
Indication
Routine prophylaxis to prevent or reduce the frequency of bleeding in patients with haemophilia B (congenital factor IX deficiency) with FIX inhibitors
Therapeutic area
Haematology

Help us improve the Therapeutic Goods Administration site